ADVERTISEMENT
  • Home
  • About us
  • Contact us
Friday, December 5, 2025
TheScript Nigeria
  • Home
  • International News
  • Local
  • Press Release
  • Economy
  • Crime
  • Business and Finance
  • Education
  • Guest Column
No Result
View All Result
  • Home
  • International News
  • Local
  • Press Release
  • Economy
  • Crime
  • Business and Finance
  • Education
  • Guest Column
No Result
View All Result
TheScript Nigeria
No Result
View All Result
Home International News

Lassa Fever kills Three in Ekiti, Cross River Government’s Firm to Produce Vaccines

thescript by thescript
March 14, 2018
in International News
0 0
0
Lassa fever: Nigeria records 16 deaths in less than one month
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

The Ekiti State Government has uncovered fresh cases of Lassa fever, which has claimed three lives.The victims were a patient who tested positive to the disease, and two others who had contact with the deceased.

Commissioner for Health, Rotimi Ojo, who made this disclosure in Ado-Ekiti yesterday, said five of the eight other suspected cases in the state tested negative, one was uncertain and the last was pending as at press time.He, however, stressed that there was no cause for alarm, noting that the state government was taking proactive steps in surveillance activities that would involve all residents due to some recorded cases and deaths in neighbouring states.

He assured that the State Disease Control team had been activated, while the process of sensitising the people with jingles, adverts and other communication media were ongoing.
Ojo said similar actions taken during the 2016 outbreak were successful, adding that the epidemic was perfectly controlled while the patient, who was properly managed, survived.

He disclosed that the isolation centre’s at Ido Federal Teaching Hospital, Ido-Ekiti; Oba Adejuyigbe General Hospital and the Ekiti State University Teaching Hospital, Ado-Ekiti were still operational.He urged health practitioners, teachers, traditional rulers, religious leaders, as well as community and opinion leaders to join hands with the state government to prevent a further spread of the disease in the state.

Meanwhile, the Cross River State government is set to commission a pharmaceutical company- CalaPharm that would manufacture drugs for the treatment of Lassa fever, meningitis and other diseases next month.

The team, which was led by the Commissioner for Information and Orientation, Mrs. Rosemary Achibong, also visited Rice City and Industrial Zone, which would house private companies under APZ.

Consultant in charge of the project, Farhan Khan, made this known yesterday in Calabar during inspection of projects undertaken by the present administration.He said the factory, which would be of World Health Organisation (WHO) standard would complement the Governor Ben Ayade Care and also focus on mother and childcare.Khan said: “Production is coming up soon, so we will be producing drugs of WHO standards and by next month, it should be commissioned because the machines are already here.”

Recommended

CARDI

Cardi B reacts to allegations of snubbing Ghanaian celebrities

6 years ago
Pictures News: Nigeria International Maritime Summit (NIMS)

Pictures News: Nigeria International Maritime Summit (NIMS)

3 years ago

Popular News

    Connect with us

    • Home
    • About
    • Contact
    • Terms of use
    Email Us: publisher@thescript.com.ng

    © 2021 TheScript Nigeria -Providing quality news and information that improves the quality of life.

    No Result
    View All Result
    • Home
    • International News
    • Local
    • Press Release
    • Economy
    • Crime
    • Business and Finance
    • Guest Column
    • Education

    © 2021 TheScript Nigeria -Providing quality news and information that improves the quality of life.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.